Fotinos, Kathryn http://orcid.org/0000-0001-8268-8360
Sansone, Andrea
Greifenberger, Alexandria
Katzman, Martin A.
Jannini, Tommaso B. http://orcid.org/0000-0003-2936-4150
Reisman, Yacov http://orcid.org/0000-0002-1513-6360
Limoncin, Erika
Jannini, Emmanuele A. http://orcid.org/0000-0002-5874-039X
Article History
Received: 19 August 2023
Revised: 5 December 2023
Accepted: 8 December 2023
First Online: 6 January 2024
Competing interests
: There are no specific conflicts of interest to declare with regards to the preparation or submission of this manuscript. However, EAJ is or has been paid consultant and/or paid speaker for Bayer, Ibsa, Menarini, Otsuka, Pfizer, Shionogi, and Viatris. MAK has participated on advisory boards and/or similar committees for GlaxoSmithKline Inc., Wyeth Pharmaceuticals, Lundbeck Canada Inc., Eli Lilly, Organon, AstraZeneca, Janssen-Ortho Inc., Shire, Bristol-Myers Squibb, Pfizer, Biovail, Genuine Health, Boehringer Ingelheim, and Solvay; has received research funding from CIHR, Sick Kids Foundation, Centre for Addiction and Mental Health Foundation, Canadian Psychiatric Research Foundation, Canadian Foundation for Innovation, GlaxoSmithKline Inc., Wyeth Pharmaceuticals, Lundbeck Canada Inc., Eli Lilly, Organon, AstraZeneca, Janssen-Ortho Inc., Solvay, Genuine Health, Shire, Bristol-Myers Squibb, Takeda, Pfizer, and Roche.